Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

05. Januar 2022 08:00 ET | Quelle: Longeveron

Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease

MIAMI, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic...
04. Januar 2022 08:00 ET | Quelle: Longeveron

Longeveron to Participate in the H.C. Wainwright BioConnect 2022 Virtual Conference

MIAMI, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related...
06. Dezember 2021 08:00 ET | Quelle: Longeveron

Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)

HLHS is a rare congenital heart defect that affects approximately 1,000 babies in the U.S. per yearOrphan Drug Designation confers certain benefits and may result in seven year market exclusivity upon...
03. Dezember 2021 16:30 ET | Quelle: Longeveron

Longeveron Inc. Announces Closing of a $20.5 Million Private Placement

MIAMI, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
01. Dezember 2021 03:17 ET | Quelle: Longeveron

Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement

MIAMI, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
30. November 2021 15:20 ET | Quelle: Longeveron

Longeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty Patients

MIAMI, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic...
18. November 2021 08:00 ET | Quelle: Longeveron

U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition

MIAMI, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
12. November 2021 08:00 ET | Quelle: Longeveron

Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2021 Financial Results

MIAMI, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
08. November 2021 08:30 ET | Quelle: Longeveron

Longeveron to Release Third Quarter 2021 Financial Results and Hold Conference Call on November 12, 2021

MIAMI, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
05. November 2021 08:30 ET | Quelle: Longeveron

Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial

MIAMI, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...

Vorherige Seite

Nächste Seite